{"id":97768,"date":"2025-12-05T09:49:08","date_gmt":"2025-12-05T09:49:08","guid":{"rendered":"https:\/\/www.europesays.com\/se\/97768\/"},"modified":"2025-12-05T09:49:08","modified_gmt":"2025-12-05T09:49:08","slug":"analyst-group-inleder-analysbevakning-av-pila-pharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/97768\/","title":{"rendered":"Analyst Group inleder analysbevakning av Pila Pharma"},"content":{"rendered":"<p><strong>Analyst Group inleder idag den 5:e december 2025 analysbevakning p\u00e5 Pila Pharma AB (\u201dPila Pharma\u201d eller \u201dBolaget\u201d) vilket innefattar aktieanalys med halv\u00e5rsvis uppdatering samt analytikerkommentarer p\u00e5 pressmeddelanden.<\/strong><\/p>\n<p><strong>Om Pila Pharma<\/strong><\/p>\n<p>Pila Pharma \u00e4r ett svenskt bioteknikbolag som utvecklar l\u00e4kemedelskandidaten XEN-D0501, med prim\u00e4rt fokus p\u00e5 en oral behandling av obesitas och typ 2-diabetes baserad p\u00e5 h\u00e4mning av TRPV1, den s\u00e5 kallade \u201dchilireceptorn\u201d. Bolagets huvudkandidat, XEN-D0501, \u00e4r en selektiv sm\u00e5molekyl\u00e4r TRPV1-antagonist med en godk\u00e4nd tablettformulering. Grundaren och Chief Scientific Officer, Dorte X. Gram, var den f\u00f6rsta att genom prekliniska studier hos Novo Nordisk visa att blockering av TRPV1 kan motverka glukosintolerans och vikt\u00f6kning. Denna uppt\u00e4ckt lade grunden f\u00f6r Bolagets patentportf\u00f6lj avseende behandling av obesitas och diabetes med TRPV1-antagonister.<\/p>\n<p>Hittills har XEN-D0501 utv\u00e4rderats i \u00e5tta kliniska studier omfattande \u00f6ver 300 personer, inklusive tv\u00e5 fas IIa-studier i patienter med obesitas och typ 2-diabetes, d\u00e4r kandidaten uppvisade god s\u00e4kerhet, f\u00f6rb\u00e4ttrad glukoskontroll samt indikationer p\u00e5 kardiovaskul\u00e4ra f\u00f6rdelar, med s\u00e4rskilt stor minskning av en hj\u00e4rtsviktsmark\u00f6r kallad ANP. Bolaget innehar \u00e4ven s\u00e4rl\u00e4kemedelsklassificering f\u00f6r XEN-D0501 inom den s\u00e4llsynta sm\u00e4rtsjukdomen erythermalgi, ett tillst\u00e5nd som k\u00e4nnetecknas av intensiva sm\u00e4rtande \u201duppflammningar\u201d utan k\u00e4nd orsak. Denna klassificering kan, om den omvandlas till faktisk s\u00e4rl\u00e4kemedelsstatus efter lyckade studier, ge betydande dataexklusivitet. Bolaget har nyligen \u00e4ven genomf\u00f6rt en preklinisk studie inom abdominellt aortaaneurysm, en kardiovaskul\u00e4r sjukdom, d\u00e4r proof of concept uppn\u00e5ddes, vilket ytterligare st\u00e4rker kandidatens potentiella kardioprotektiva effekter.<\/p>\n<p>Pila Pharma avser nu att genomf\u00f6ra prekliniska obesitasstudier i samarbete med Gubra i tv\u00e5 etablerade r\u00e5ttmodeller f\u00f6r obesitas (DIO- och Zuckerr\u00e5ttor) f\u00f6r att uppn\u00e5 proof of concept inom obesitas, finansierat genom en nyligen avslutad och \u00f6vertecknad f\u00f6retr\u00e4desemission. Ambitionen \u00e4r d\u00e4refter att driva tv\u00e5 parallella utvecklingssp\u00e5r, i \u00f6verviktiga patienter med och utan typ 2-diabetes, f\u00f6r att skapa ett omfattande och kommersiellt attraktivt datapaket. Dessa skulle omfatta fas Ib\/IIa-studier, dels i personer med obesitas, dels i personer med obesitas och diabetes, med tre m\u00e5naders behandling. Studierna ska fastst\u00e4lla maximal tolererad dos, bekr\u00e4fta s\u00e4kerhetsprofilen och generera prelimin\u00e4r data avseende viktreduktion som kan ligga till grund f\u00f6r ett partnerskap eller ett potentiellt f\u00f6rv\u00e4rv av en st\u00f6rre l\u00e4kemedelsakt\u00f6r, samt positionera XEN-D0501 som en potentiell f\u00f6rstklassig oral behandling f\u00f6r obesitas och obesitasrelaterade komorbiditeter.<\/p>\n<p><strong>St\u00e4rker Bolagets Scientific Advisory Board genom rekrytering av expert inom preklinisk obesitas- och metabolismforskning<\/strong><\/p>\n<p>Pila Pharma meddelade den 4:e december att professor Thomas Lutz, DVM, PhD, vid Universit\u00e4t Z\u00fcrich har anslutit sig till Bolagets Scientific Advisory Board. Professor Lutz \u00e4r en internationellt erk\u00e4nd expert inom preklinisk obesitas- och metabolismforskning. Tillskottet av professor Lutz inneb\u00e4r en f\u00f6rst\u00e4rkning av Pila Pharmas vetenskapliga kompetens i ett skede n\u00e4r Bolaget st\u00e5r inf\u00f6r prekliniska obesitasstudier i DIO- och Zuckerr\u00e5ttor. Medan Bolagets befintliga r\u00e5dgivare prim\u00e4rt representerar klinisk expertis inom obesitas och diabetes, tillf\u00f6r professor Lutz djupg\u00e5ende preklinisk sakkunskap som \u00e4r central f\u00f6r att utv\u00e4rdera och tolka de mekanistiska effekterna av XEN-D0501. Detta kompletterar forskningsstrategin och st\u00e4rker Pila Pharmas f\u00f6rm\u00e5ga att bygga ett robust och kommersiellt attraktivt datapaket inf\u00f6r kommande kliniska utvecklingssteg. Professor Lutz har dessutom en framtr\u00e4dande position inom det internationella forskarsamh\u00e4llet, rekryteringen kan d\u00e4rmed \u00e4ven f\u00f6rv\u00e4ntas bidra till \u00f6kad extern synlighet och vetenskaplig tyngd inf\u00f6r den kommande starten av Pila Pharmas obesitasstudier, som utg\u00f6r en av Bolagets n\u00e4rmast liggande milstolpar.<\/p>\n<p><strong>Analyst Group kommer att \u00e5terkomma med en fullst\u00e4ndig aktieanalys av Pila Pharma. Bolaget kommer \u00e4ven att presentera p\u00e5 v\u00e5r kapitalmarknadsdag den 10:e december.<\/strong><\/p>\n<p><strong>Analyst Group today, December 5, 2025, initiates equity research coverage on Pila Pharma AB (\u201cPila Pharma\u201d or \u201cthe Company\u201d). The coverage includes equity research with biannual updates as well as analyst comments on press releases.<\/strong><\/p>\n<p><strong>About Pila Pharma<\/strong><\/p>\n<p>Pila Pharma is a Swedish biotechnology company developing the drug candidate XEN-D0501, primarily focused on an oral treatment for obesity and type 2 diabetes based on inhibition of TRPV1, the so-called \u201cchili receptor.\u201d The Company\u2019s lead candidate, XEN-D0501, is a selective small-molecule TRPV1 antagonist with an approved tablet formulation. Founder and Chief Scientific Officer Dorte X. Gram were the first to demonstrate, through preclinical studies at Novo Nordisk, that blocking TRPV1 can counteract glucose intolerance and weight gain. This discovery laid the foundation for the Company\u2019s patent portfolio relating to the treatment of obesity and diabetes using TRPV1 antagonists.<\/p>\n<p>To date, XEN-D0501 has been evaluated in eight clinical trials involving over 300 persons, including two Phase IIa studies in patients with obesity and type 2 diabetes, where the candidate demonstrated good safety, improved glucose control, and indications of cardiovascular benefits, with an especially large reduction in a heart failure biomarker called ANP. The Company also holds orphan drug designation for XEN-D0501 in the rare pain disorder erythromelalgia, a condition characterized by intense episodes of \u201cflare-ups\u201d with pain occurring without a known cause. This designation, if converted to actual orphan drug status, which is pending successful trials, could provide significant data exclusivity. The Company has most recently also conducted a preclinical study within abdominal aortic aneurysm, a cardiovascular disease, achieving proof of concept, further strengthening the perceived cardio-protective benefits of the candidate.<\/p>\n<p>Pila Pharma is now to conduct preclinical obesity studies in collaboration with Gubra in two established obesity rat models (DIO and Zucker rats) to achieve proof-of-concept within obesity, funded by a recently completed and oversubscribed rights issue. The ambition thereafter is to pursue two parallel development tracks, in overweight patients with and without type 2 diabetes, to build a comprehensive and commercially attractive data package. These would comprise of Phase Ib\/IIa trials, in people living with obesity, and in people living with obesity and diabetes of three months treatment. The trials will aim to determine the maximum tolerable dose, confirm the safety profile, and generate preliminary data on weight reduction that could form the basis for a partnership\/acquisition with a larger pharmaceutical company and position XEN-D0501 as a potential first-in-class oral treatment for obesity and obesity-related comorbidities.<\/p>\n<p><strong>Strengthening the Company\u2019s Scientific Advisory Board through the recruitment of an expert in preclinical obesity and metabolic research<\/strong><\/p>\n<p>On December 4, Pila Pharma announced that Professor Thomas Lutz, DVM, PhD, from the University of Zurich, has joined the Company\u2019s Scientific Advisory Board. Professor Lutz is an internationally recognized expert in preclinical obesity and metabolic research. His appointment strengthens Pila Pharma\u2019s scientific capabilities at a time when the Company is preparing to initiate preclinical obesity studies in DIO and Zucker rats. While the Company\u2019s existing advisors primarily represent clinical expertise in obesity and diabetes, Professor Lutz brings deep preclinical knowledge that is essential for evaluating and interpreting the mechanistic effects of XEN-D0501. This addition complements the Company\u2019s research strategy and enhances Pila Pharma\u2019s ability to build a robust and commercially attractive data package ahead of future clinical development steps. Moreover, Professor Lutz holds a prominent position within the international scientific community, and his recruitment is therefore expected to further increase external visibility and scientific credibility ahead of the upcoming launch of Pila Pharma\u2019s obesity studies, which constitute one of the Company\u2019s key near-term milestones.<\/p>\n<p><strong>Analyst Group will return with an equity research report on Pila Pharma. The Company will also present at our capital markets on December 10th.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Analyst Group inleder idag den 5:e december 2025 analysbevakning p\u00e5 Pila Pharma AB (\u201dPila Pharma\u201d eller \u201dBolaget\u201d) vilket&hellip;\n","protected":false},"author":2,"featured_media":75242,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69],"tags":[113,112,34,31,33,32,30],"class_list":{"0":"post-97768","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-halsa","8":"tag-halsa","9":"tag-health","10":"tag-se","11":"tag-svenska","12":"tag-sverige","13":"tag-sweden","14":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115666338680919106","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/97768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=97768"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/97768\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/75242"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=97768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=97768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=97768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}